Abstract Details

Title COVID-19 Cytokine Storm in Myasthenia Gravis Treated with Mesenchymal Stem Cells: A Case Report

Topic Autoimmune Neurology

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-002

Objective NA

Background Coronavirus disease 2019 (COVID-19) continues to plague especially the immunocompromised, and yet little is known regarding its treatment on patients who present clinically similar like those with Myasthenia Gravis (MG) in crisis.

Design/Methods We examined the case of a 49-year-old female with MG secondary to malignant thymoma who went into COVID-19 cytokine storm and during her recovery, also suffered a post-infectious myasthenic crisis.

Results After 10 days of intubation and completing 4 doses of mesenchymal stem cell therapy (MSc), the patient significantly improved and was discharged ambulatory with assistance oxygen-requiring on nasal cannula coexistent with a decrease in measured cytokine levels.

Conclusions Immunosuppressive treatment, defective immunoregulatory mechanisms, pro-inflammatory state and respiratory muscle weakness in MG has all shown worse outcomes in COVID-19. Both diseases share a common pathomechanism and recovery depends on a healthy T-cell regulatory and B-cell response. MSc, with its immunomodulatory and anti-inflammatory properties, is thus promising in COVID-19 treatment in the setting of autoimmunity.

Authors/Disclosures
Aldanica Olano PRESENTER	Aldanica Olano has nothing to disclose.
Mark Anthony J. Sta. Maria, MD (The Medical City)	Dr. Sta. Maria has nothing to disclose.
Genica Lynne Maylem	No disclosure on file
Marc Joseph Oliver Buensalido, MD (The Medical City Hospital)	Marc Joseph Oliver Buensalido has nothing to disclose.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��